225,027 Shares in Exelixis, Inc. $EXEL Bought by New Vernon Capital Holdings II LLC

Key Points

• New Vernon Capital Holdings II LLC acquired 225,027 shares of Exelixis, Inc. valued at approximately $8,308,000, representing a 0.08% ownership stake in the company.
• Exelixis reported $0.75 earnings per share for the last quarter, exceeding analysts' estimates, despite a 10.8% revenue decline from the previous year.
• The stock currently has an average rating of "Moderate Buy" among analysts, with a reported average price target of $44.06.

New Vernon Capital Holdings II LLC bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 225,027 shares of the biotechnology company's stock, valued at approximately $8,308,000. New Vernon Capital Holdings II LLC owned about 0.08% of Exelixis as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of EXEL. Hemington Wealth Management boosted its position in shares of Exelixis by 211.3% during the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after buying an additional 522 shares during the last quarter. Colonial Trust Co SC boosted its position in shares of Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after buying an additional 765 shares during the last quarter. Bartlett & CO. Wealth Management LLC purchased a new position in shares of Exelixis during the first quarter valued at approximately $37,000. Costello Asset Management INC purchased a new position in shares of Exelixis during the first quarter valued at approximately $39,000. Finally, Harbour Investments Inc. boosted its position in shares of Exelixis by 900.0% during the first quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company's stock valued at $41,000 after buying an additional 990 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Stock Down 0.4%

NASDAQ:EXEL traded down $0.15 during trading hours on Wednesday, hitting $38.14. 727,676 shares of the company's stock traded hands, compared to its average volume of 2,991,480. The firm has a market cap of $10.27 billion, a P/E ratio of 18.32, a P/E/G ratio of 0.78 and a beta of 0.32. Exelixis, Inc. has a 52 week low of $25.17 and a 52 week high of $49.62. The business's fifty day simple moving average is $40.38 and its two-hundred day simple moving average is $39.61.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm's quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter last year, the company earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. On average, analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Benchmark reaffirmed a "neutral" rating on shares of Exelixis in a report on Monday, June 23rd. Guggenheim reaffirmed a "buy" rating and issued a $45.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Citigroup upped their target price on Exelixis from $45.00 to $56.00 and gave the company a "buy" rating in a report on Thursday, May 15th. HC Wainwright reduced their target price on Exelixis from $53.00 to $46.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Finally, UBS Group set a $38.00 price target on shares of Exelixis and gave the stock a "neutral" rating in a research note on Wednesday, July 30th. Thirteen research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $44.06.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.